【作者】 王记；

【导师】 姚亚丽；

【作者基本信息】 兰州大学 ， 内科学， 2013， 硕士

【摘要】 目的：本课题通过观察阿托伐他汀在在心衰药物基础治疗上对慢性心力衰竭患者QT离散度(QTd)及N末端脑钠肽前体(NT-proBNP)的影响,并探讨其作用机制。方法：参考全国高等学校教材《内科学》第7版慢性心力衰竭诊断标准,采用随机数字表法将70例患者随机分为两组,治疗组35例,对照组35例,两组患者在入组时一般性资料方面(年龄、性别、病程、病情)均无显著性差异。对照组给予慢性心衰药物基础治疗,治疗组在慢性心衰药物基础治疗上加服阿托伐他汀,疗程为12周。观察治疗前后慢性心衰患者QTd及NT-proBNP的变化。结果：(1)两组治疗前后QTd及QTcd明显缩小,治疗组QTd及QTcd缩小优于对照组(P<0.01)。(2)两组治疗后,治疗组血浆NT-proBNP均明显下降(P<0.01),与对照组治疗后比较差异也有统计学意义(P<0.05)。结论：通过本次临床观察,结果显示阿托伐他汀联合慢性心衰药物基础治疗可缩短慢性心力衰竭患者的QT离散度并降低NT-proBNP.更多还原

【Abstract】 Objective:1:To study the effects of atorvastatin on QTd (qt dispersion) and NT-proBNP in Patients with chronic heart failure, and investigate the possible mechanisms.Methods:Refer to the Diagnostic criteria of chronic heart failure of The national higher school teaching materials internal medicine,The seventh edition.the Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult,70Patients with chronic heart failure were randomly divided into two groups,35patients were treated with basic Western medicine as control group;35patients were treated with combination therapy of atorvastatin with Western medicine as treatment group.QTd and NT-proBNP levels were measured before and after12week treatmeant.Results:(1)in two groups,QTd and QTcd levels were both significantly reduced after treatment, especially in treatment group.(2)After treatment, NT-proBNP in blood plasma was decreasing significantly in treatment group(P<0.01), Compared with control group,the decreasing was significantly(P<0.05).Conclusion:Compared with control group, combination therapy of atorvastatin with basic Western medicine has the obvious curative effect for Patients with chronic heart failure.更多还原